Sun BioPharma, Inc. (OTCMKTS:SNBP) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On March 30, 2017, Sun BioPharma, Inc. (the Company) issued a
press release providing a clinical trial update and announcing
its financial results for the fourth quarter and full year ended
December 31, 2016. The full text of the press release is set
forth in Exhibit 99.1 attached hereto and is incorporated by
reference in this current report on Form 8-K as if fully set
forth herein.
The Company is furnishing the information contained in this
report, including Exhibit 99.1, to Item 2.02 of Form 8-K
promulgated by the Securities and Exchange Commission (the SEC).
This information shall not be deemed to be filed with the SEC for
the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed to be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
|
99.1 |
Press releaseproviding a clinical trial update and |
About Sun BioPharma, Inc. (OTCMKTS:SNBP)
Sun BioPharma, Inc., formerly Cimarron Medical, Inc., is a clinical stage drug development company. The Company is a biopharmaceutical company focused on developing therapies for pancreatic diseases. It is engaged in the commercial development of a polyamine analogue for pancreatic cancer and for a second indication in chronic pancreatitis. The Company’s products include SBP-101, SBP-102 and SBP-103. Its SBP-101 is a polyamine compound and exhibits specificity for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. It develops SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma. The SBP-102 product is in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. The SBP-103 product is in non-clinical exploratory evaluation. The Company has enrolled first patient in its Phase I clinical trial of SBP-101 in patients with previously treated pancreatic cancer. Sun BioPharma, Inc. (OTCMKTS:SNBP) Recent Trading Information
Sun BioPharma, Inc. (OTCMKTS:SNBP) closed its last trading session 00.00 at 2.75 with 1,000 shares trading hands.